

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

3555 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

3557 **Mutual ATRaction: Assessing Synergy of Berzosertib with Sacituzumab Govitecan**
Stephanie A. Berg and Atish D. Choudhury
See related article, p. 3603

3560 **BCR/Integrin Interaction in CLL: A Physiologic Remnant with Clinical Relevance**
Erika Tissino, Riccardo Bomben, Valter Gattei, and Antonella Zucchetto
See related article, p. 3612

3563 **Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond**
David J. Cantor and Charu Aggarwal
See related article, p. 3641

CCR Perspectives in Regulatory Science and Policy

3566 **Driving Diversity and Inclusion in Cancer Drug Development – Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges**
Lola A. Fashoyin-Aje, Craig Tendler, Bea Lavery, Serban Ghiorgiu, Brittany Gerald, Chitkala Kalidas, Nicole Richie, Kathleen Winson, Nicholas J.H. Warren, Tristen V. Tellman, Jon Retzlaff, Margaret Foti, and Richard Pazdur

CCR Drug Updates

3573 **FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors**
Elizabeth S. Duke, Diana Bradford, Michelle Marcovitz, Anup K. Amatya, Pallavi S. Mishra-Kalyani, Emily Nguyen, Lauren S.L. Price, Jeanne Fourie Zirkelbach, Yangbing Li, Youwei Bi, Jeffrey Kraft, Sarah E. Dorff, Barbara Scepura, Maritsa Stephenson, Idara Ojofeitimi, Abhilasha Nair, Yu Han, Zivana Tezak, Steven J. Lemery, Richard Pazdur, Erin Larkins, and Harpreet Singh

Review

3579 **Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer**
Juan Bautista Blaquier, Sandra Ortiz-Cuaran, Biagio Ricciuti, Laura Mezquita, Andrés Felipe Cardona, and Gonzalo Recondo

CLINICAL TRIALS: TARGETED THERAPY

3592 **Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors**
Maria Vieito, Victor Moreno, Anna Spreafico, Irene Brana, Judy S. Wang, Meir Preis, Tatiana Hernández, Sofia Genta, Aaron R. Hansen, Bernard Doger, Vladimir Galvao, Laurie Lenox, Regina J. Brown, Anna Kalota, Jaydeep Mehta, Friederike Pastore, Bharvin Patel, Pankaj Mistry, Junchen Gu, Josh Lauring, and Manish R. Patel

3603 **Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial**
Melissa L. Abel, Nobuyuki Takahashi, Cody Peer, Christophe E. Redon, Samantha Nichols, Rasa Vilimas, Min-Jung Lee, Sunmin Lee, Meenakshi Shelat, Robbie Kattappuram, Linda Sciuto, Danielle Pinkiert, Chante Graham, Donna Butcher, Baktiar Karim, Ajit Kumar Sharma, Justin Malin, Rajesh Kumar, Christopher W. Schultz, Shubhank Goyal, Jaydira del Rivero, Manan Krishnamurthy, Deep Upadhyay, Brett Schroeder, Tristan Sissung, Manoj Tyagi, Jung Kim, Yves Pommier, Mirit Aladjem, Mark Raffeld, William Douglas Figg, Jane Trepel, Liqiang Xi, Parth Desai, and Anish Thomas
See related commentary, p. 3557

3612 **CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy**
Anfal Alsadhan, Jonathan Chen, Erika M. Gaglione, Chingiz Underbayev, Pamela L. Tuma, Xin Tian, Lita A. Freeman, Sivasubramanian Baskar, Pia Nierman, Susan Soto, Andy Itsara, Inhye E. Ahn, Clare Sun, Elena Bibikova, Tanja Nicole Hartmann, Maissa Mhibik, and Adrian Wiestner
See related commentary, p. 3560

TABLE OF CONTENTS

3622 **A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis**

John Mascarenhas, Anna Rita Migliaccio, Heidi Kosiorek, Rupali Bhawe, Jeanne Palmer, Andrew Kuykendall, Ruben Mesa, Raajit K. Rampal, Aaron T. Gerds, Abdulraheem Yacoub, Kristen Pettit, Moshe Talpaz, Rami Komrokji, Marina Kremyanskaya, Agapito Gonzalez, Frank Fabris, Kathryn Johnson, Mikaela Dougherty, Erin McGovern, Juan Arango Ossa, Dylan Domenico, Noushin Farnoud, Rona Singer Weinberg, Amy Kong, Vesna Najfeld, Alessandro Maria Vannucchi, Francesca Arciprete, Maria Zingariello, Mario Falchi, Mohamed E. Salama, Carolyn Mead-Harvey, Amylou Dueck, Lilian Varricchio, and Ronald Hoffman

3633 **Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer**

Steven B. Maron, Walid Chatila, Henry Walch, Joanne F. Chou, Nicholas Ceglia, Ryan Ptashkin, Richard Kinh Gian Do, Viktoriya Paroder, Neeta Pandit-Taskar, Jason S. Lewis, Tiago Biachi De Castria, Shalom Sabwa, Fiona Socolow, Lara Feder, Jasmine Thomas, Isabell Schulze, Kwanghee Kim, Arijh Elzein, Viktoria Bojilova, Matthew Zatzman, Umesh Bhanot, Rebecca J. Nagy, Jeeyun Lee, Marc Simmons, Michal Segal, Geoffrey Yuyat Ku, David H. Ilson, Marinela Capanu, Jaclyn F. Hechtman, Taha Merghoub, Sohrab Shah, Nikolaus Schultz, David B. Solit, and Yelena Y. Janjigian

3641 **Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)**

Shirish M. Gadgeel, Jieliang Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner, Timothy F. Burns, Asma Taj, Wallace L. Akerley III, Konstantin H. Dragnev, Noel Laudi, Mary W. Redman, Jhanelle E. Gray, David R. Gandara, and Karen Kelly

See related commentary, p. 3563

CLINICAL TRIALS: IMMUNOTHERAPY

3650 **A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma**

Yun Bin Lee, Joon Yeul Nam, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Hyo-Cheol Kim, Jin Chul Paeng, Jung-Hwan Yoon, and Yoon Jun Kim

3659 **A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor**

Suzanne George, Michael C. Heinrich, Neeta Somaiah, Peter Oppelt, Robert McLeod, Satoshi Nishioka, Madan G. Kundu, Xiaozhong Qian, Prasanna Kumar, Abderrahmane Laadem, Yvonne Lau, Brittany P. Tran, Maura Fallon, Ololade Dosunmu, Julia Shi, and Yoichi Naito

PRECISION MEDICINE AND IMAGING

3668 **Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction**

Keyan Salari, Debasish Sundi, Jason J. Lee, Shulin Wu, Chin-Lee Wu, Gabrielle DiFiore, Q. Robert Yan, Andrew Pienkny, Chi K. Lee, Daniel Oberlin, Greg Barne, Joel Piser, Robert Kahn, Edward Collins, Kevin G. Phillips, Vincent M. Caruso, Mahdi Goudarzi, Monica Garcia-Ransom, Peter S. Lentz, Martha E. Evans-Holm, Andrew R. MacBride, Daniel S. Fischer, Iden J. Haddadzadeh, Brian C. Mazzearella, Joe W. Gray, Theresa M. Koppie, Vincent T. Biccoca, Trevor G. Levin, Yair Lotan, and Adam S. Feldman

3681 **Evaluation of Somatic Mutations in Urine Samples as a Noninvasive Method for the Detection and Molecular Classification of Endometrial Cancer**

Laura Costas, Irene Onieva, Beatriz Pelegrina, Fátima Marin, Álvaro Carmona, Marta López-Querol, Jon Frias-Gomez, Paula Peremiquel-Trillas, José Manuel Martínez, Eduard Dorca, Joan Brunet, Marta Pineda, Jordi Ponce, Xavier Matias-Guiu, Silvia de Sanjosé, Francesc Xavier Bosch, Laia Alemany, and Sonia Paytubi

3691 **Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)**

Holly Tovey, Orsolya Sipos, Joel S. Parker, Katherine A. Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Anita Grigoriadis, Andrew Tutt, and Maggie Chon U. Cheang

3706 **Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression**

Stephanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield, Eduardo Gonzalez-Ochoa, Jeffrey P. Bruce, Derek Wong, Arnavaz Danesh, Dax Torti, Jonathan Torchia, Alexander Fortuna, Sharanjit Singh, Matthew Irving, Kayla Marsh, Bernard Lam, Vanessa Speers, Aleksandra Yosifova, Ana Oaknin, Ainhua Madariaga, Neesha C. Dhani, Valerie Bowering, Amit M. Oza, and Trevor J. Pugh

TABLE OF CONTENTS

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

3717 **Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer**

Nicole A. Traphagen, Gary N. Schwartz, Steven Tau, Alyssa M. Roberts, Amanda Jiang, Sarah R. Hosford, Jonathan D. Marotti, Abigail E. Goen, Bianca A. Romo, Anneka L. Johnson, Emily-Claire K. Duffy, Eugene Demidenko, Paul Heverly, Yaron Mosesson, Shannon M. Soucy, Fred Kolling, and Todd W. Miller

3729 **Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features**

Hanne Lefrère, Kat Moore, Giuseppe Floris, Joyce Sanders, Iris M. Seignette, Tycho Bismeijer, Dennis Peters, Annegien Broeks, Erik Hooijberg, Kristel Van Calsteren, Patrick Neven, Ellen Warner, Fedro Alessandro Peccatori, Sibylle Loibl, Charlotte Maggen, Sileny N. Han, Katarzyna J. Jerzak, Daniela Annibali, Diether Lambrechts, Karin E. de Visser, Lodewyk Wessels, Liesbeth Lenaerts, and Frédéric Amant

3744 **Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis**

Teresa González-Muñoz, Angela Di Giannatale, Susana García-Silva, Vanesa Santos, Sara Sánchez-Redondo, Claudia Savini, Osvaldo Graña-Castro, Carmen Blanco-Aparicio, Suzanne Fischer, Olivier De Wever, Edgar Creus-Bachiller, Sara Ortega-Bertran, David J. Pisapia, Jose L. Rodríguez-Peralto, Juana Fernández-Rodríguez, Cleofé Romagosa Pérez-Portabella, Rita Alaggio, Maria Serena Benassi, Laura Pazzaglia, Katia Scotlandi, Nancy Ratner, Kaleb Yohay, Charles P. Theuer, and Héctor Peinado

3759 **A Novel *HOXA10*-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Ductal Adenocarcinoma**

Sophia G. Kisling, Pranita Atri, Ashu Shah, Jesse L. Cox, Sunandini Sharma, Lynette M. Smith, Dario Gherzi, and Surinder K. Batra

3771 **Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors**

Claire Gallois, Matteo Landi, Julien Taieb, Marine Sroussi, Bahar Saberzadeh-Ardestani, Antoine Cazelles, Sara Lonardi, Francesca Bergamo, Rossana Intini, Giulia Maddalena, Filippo Pietrantonio, Francesca Corti, Margherita Ambrosini, Antonia Martinetti, Marco Maria Germani, Chiara Boccaccio, Guglielmo Vetere, Sophie Mouillet-Richard, Aurélien de Reynies, Frank A. Sinicrope, Chiara Cremolini, and Pierre Laurent-Puig

3779 **Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages**

Wei Yuan, Qian Zhang, Danling Gu, Chenfei Lu, Deobrat Dixit, Ryan C. Gimple, Yisu Gao, Jiancheng Gao, Daqi Li, Danyang Shan, Lang Hu, Lu Li, Yangqing Li, Shusheng Ci, Hao You, Linping Yan, Kexin Chen, Ningwei Zhao, Chuanhai Xu, Jianyun Lan, Dong Liu, Junxia Zhang, Zhumei Shi, Qiulian Wu, Kailin Yang, Linjie Zhao, Zhixin Qiu, Deguang Lv, Wei Gao, Hui Yang, Fan Lin, Qianghu Wang, Jianghong Man, Chaojun Li, Weiwei Tao, Sameer Agnihotri, Xu Qian, Stephen C. Mack, Nu Zhang, Yongping You, Jeremy N. Rich, Guan Sun, and Xiuxing Wang

3793 **Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer**

Abigail C. Cornwell, Arwen A. Tisdale, Swati Venkat, Kathryn E. Maraszek, Abdulrahman A. Alahmari, Anthony George, Kristopher Attwood, Madison George, Donald Rempinski, Janusz Franco-Barraza, Mukund Seshadri, Mark D. Parker, Eduardo Cortes Gomez, Christos Fountzilas, Edna Cukierman, Nina G. Steele, and Michael E. Feigin

3813 **Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment**

Jonathan M.J. Derry, Connor Burns, Jason P. Frazier, Emily Beirne, Marc Grenley, Christopher C. DuFort, Emily Killingbeck, Michael Leon, Claire Williams, Mark Gregory, Jeffrey Houlton, Daniel Clayburgh, Paul Swiecicki, Dennis Huszar, Allison Berger, and Richard A. Klinghoffer

CORRECTION

3826 **Correction: ATF3 Repression of BCL-X_L Determines Apoptotic Sensitivity to HDAC Inhibitors Across Tumor Types**

Anderly C. Chüeh, Janson W.T. Tse, Michael Dickinson, Paul Ioannidis, Laura Jenkins, Lars Togel, BeeShin Tan, Ian Luk, Mercedes Davalos-Salas, Rebecca Nightingale, Matthew R. Thompson, Bryan R.G. Williams, Guillaume Lessene, Erinna F. Lee, Walter D. Fairlie, Amardeep S. Dhillon, and John M. Mariadason

TABLE OF CONTENTS

ABOUT THE COVER

The cover shows the section of a breast tumor biopsy from a postpartum breast cancer patient. Multiplex immunohistochemical staining shows the simultaneous density and clustering of the CD20, CD8, CD3 and CD138 markers. For details, see the article by Lefrère and colleagues on page 3729 of this issue. (Image produced by coauthor Iris M. Seignette on a Ventana Discovery Ultra automated stainer [Ventana Medical Systems] using the Opal Polaris 7-Color Manual IHC Kit.)

doi: 10.1158/1078-0432.CCR-29-18-CVR

